Videos
The New York State Cellular Therapy Consortium
This is a clinically oriented educational program intended for hematologists, oncologists, pharmacists, pathologists, and other healthcare professionals that may diagnose, treat, or manage patients with cancer. The goal is to educate participants ...
Roswell Park Welcomes New Vice Chair of Clinical Affairs: Dr. Peter Maslak
Peter Maslak, MD, is an expert Hematologic Oncologist, joining Roswell Park as Vice Chair of Clinical Affairs, Director of Flow Cytometry in the Immune Monitoring Shared Resource and the Technical Director of the Flow Cytometry Lab.
Roswell Park Welcomes New Chief of Lymphoma Clinical Section: Dorothy Pan, MD
Dorothy Pan, MD, is joining Roswell Park Comprehensive Cancer Center as the Chief of the Lymphoma Clinical Section in the Department of Medicine.
CAR T-Cell Therapy Proves Effective in First Trial in Patients with Resistant Multiple Myeloma
A therapy made of immune system T cells engineered to target a somewhat enigmatic cell protein called GPRC5D antigen produced impressive results in its first clinical trial in patients with multiple myeloma, researchers at Memorial Sloan ...
Physician-Scientist Marco Davila, MD, PhD, Joins Growing Roswell Park Cellular Therapy Program
Following a national search, Roswell Park Comprehensive Cancer Center has appointed Marco Davila, MD, PhD, as Senior Vice President and Associate Director for Translational Research and Vice-Chair for Cellular Therapies.
Reaching Deep Remissions with a New Therapy for Multiple Myeloma Patients
Roswell Park is spearheading efforts to study innovative CAR T-cell therapies in addition to offering traditional treatment approaches.
Warning Signs of Hematologic Malignancies in the Primary Care Setting
Eunice Wang, MD, Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center, offers guidance on what red flags may indicate a hematologic cancer in your patients to help you identify these complex and often difficult-to-treat ...
Benefits of Combining Beta-Blocker and Checkpoint Inhibitor
The same biochemical triggers that spur a “fight or flight” response when we encounter threats may help tumor cells to thrive.
Mapping the Battlefield: Imaging of Multiple Myeloma
Jens Hillengass, MD, shares a history of myeloma imaging, the variety of sophisticated imaging techniques available, and shares several examples to help determine diagnosis.
News
Investigators at Roswell Park Comprehensive Cancer Center hope a new clinical trial will pave the way for a new time-limited, oral-delivery treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) ...
As work advances on a significant expansion of its cellular therapy production and research facilities, Roswell Park Comprehensive Cancer Center has named Yeong “Christopher” Choi, PhD, MBA, as Senior Vice President of Industry Partnerships ...
A clinical trial led by Jens Hillengass, MD, PhD, Chief of Myeloma at Roswell Park Comprehensive Cancer Center, shows that exercise may have the power to strengthen the immune system in those patients, providing a nonpharmaceutical method ...
BUFFALO, N.Y. — Eunice S. Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, led a research effort that supports the addition of gemtuzumab ozogamicin—a CD33-directed antibody-drug conjugate—to standard induction ...
Pediatric Multicenter Study Shows Targeted Therapy for High-Risk Hodgkin Lymphoma Reduces Relapse
BUFFALO, N.Y. and ATLANTA, GA. — A targeted therapy for children with high-risk Hodgkin lymphoma (HL) was shown to significantly reduce relapse rates when tested in a large multicenter clinical trial conducted by the Children’s Oncology ...
Roswell Park-CIM Study Shows Novel Agent Can Overcome Immune Dysfunction in Cancer
Preclinical/clinical findings on VSSP in metastatic kidney cancer support development of new treatment approach.
From ASCO 2022: Brentuximab Vedotin and Chemotherapy an Effective Treatment for Hodgkin Lymphoma
Children’s Oncology Group study shows benefit for children and adolescents with high-risk HL treated with the combination
Roswell Park Expert to Present on Effectiveness of New Combination for Acute Myeloid Leukemia
Results on FLT3 inhibitor crenolanib in combination with chemotherapy to be presented in talk at ASCO 2022
A multidisciplinary research team led by Song Yao, PhD, Professor of Oncology in the Department of Cancer Prevention and Control at Roswell Park Comprehensive Cancer Center and Kara Kelly, MD, Chair of the Roswell Park Oishei Children’s ...
This site is intended for healthcare professionals